By performing computational analyses, followed by validation in mouse models, cell-based systems, and patient-derived models, we identified peroxiredoxin 2 (PRDX2) as a candidate target for HCC prevention in MASH. This evidence concerns the gene PRDX2 and hepatocellular carcinoma.